title: Statin use in relation to prostate cancer outcomes in a population-based patient cohort study.
abstract: BACKGROUND
  We investigated associations between statin use begun before prostate cancer (PCa) diagnosis and PCa recurrence/progression and PCa-specific mortality (PCSM) in a prospective, population-based cohort study.
  
  
  METHODS
  The analysis included 1,001 PCa patients diagnosed in 2002-2005 in King County, Washington. Statin use was assessed at the time of diagnosis using a detailed in-person interview. Prostate cancer recurrence/progression events and cause-specific survival were ascertained from a follow-up survey and the SEER registry. Multivariable competing risk and Cox proportional hazards regression models were used to assess the risk of PCa outcomes according to categories of statin use.
  
  
  RESULTS
  Of the 1,001 PCa patients in our study, 289 men were ever users of statin drugs. During follow-up, we identified 151 PCa recurrence/progression events and 123 total deaths, including 39 PCa-specific deaths. In unadjusted analysis, the risk of PCSM was significantly lower for statin users compared to non-users (1% vs. 5% at 10 years; P < 0.01). In multivariable analysis, the adjusted hazard ratio of PCSM for statin users versus non-users was 0.19 (95% CI: 0.06, 0.56). Statin use was not associated with overall PCa recurrence/progression and other-cause mortality.
  
  
  CONCLUSIONS
  Statin use begun before PCa diagnosis was unrelated to PCa recurrence/progression but was associated with a decrease in risk of PCSM.
authors: Department of Epidemiology, GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
authors: Milan S
authors: MS
authors: Geybels
authors: Jonathan L
authors: JL
authors: Wright
authors: Sarah K
authors: SK
authors: Holt
authors: Suzanne
authors: S
authors: Kolb
authors: Ziding
authors: Z
authors: Feng
authors: Janet L
authors: JL
authors: Stanford
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D015331:Cohort Studies; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011159:Population Surveillance / Q000379:methods; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D012042:Registries; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
references: Int J Cancer. 2008 Aug 15;123(4):899-904
references: 18491405
references: Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e13-7
references: 22652109
references: Nat Rev Cancer. 2005 Dec;5(12):930-42
references: 16341084
references: Prostate Cancer Prostatic Dis. 2011 Mar;14(1):63-8
references: 20938462
references: BJU Int. 2013 Mar;111(3 Pt B):E71-7
references: 23017100
references: Cancer. 2012 Aug 15;118(16):4046-52
references: 22180145
references: J Urol. 2011 Apr;185(4):1268-73
references: 21334020
references: Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):713-8
references: 20452139
references: Circulation. 2000 Jan 18;101(2):207-13
references: 10637210
references: Eur Urol. 2011 Jun;59(6):893-9
references: 21388736
references: JAMA. 2005 Jul 27;294(4):433-9
references: 16046649
references: Eur J Cancer. 2011 Apr;47(6):819-30
references: 21354784
references: J Clin Invest. 2005 Apr;115(4):959-68
references: 15776112
references: Urology. 2009 Jan;73(1):158-62
references: 18722651
references: Curr Urol Rep. 2008 May;9(3):189-96
references: 18765112
references: Am J Epidemiol. 2008 Aug 1;168(3):250-60
references: 18556686
references: J Natl Cancer Inst. 2011 Jun 8;103(11):885-92
references: 21498780
references: J Urol. 2010 Jan;183(1):118-24
references: 19913252
references: Urology. 2005 Dec;66(6):1150-4
references: 16360430
references: Br J Cancer. 2012 May 8;106(10):1689-96
references: 22531631
references: Prostate. 2010 Jul 1;70(10):1094-101
references: 20503394
references: Cancer. 2010 Jul 15;116(14):3389-98
references: 20586112
references: Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74
references: 16798415
references: Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2665-74
references: 22949700
references: J Urol. 2012 Sep;188(3):786-91
references: 22818136
references: J Clin Oncol. 2010 Jun 1;28(16):2653-9
references: 20421534
references: Cancer. 2009 Oct 1;115(19):4477-87
references: 19691097
references: N Engl J Med. 2012 Nov 8;367(19):1792-802
references: 23134381
references: J Clin Oncol. 2012 Oct 1;30(28):3540-4
references: 22927523
references: BJU Int. 2011 Oct;108(8 Pt 2):E211-6
references: 21453350
references: PLoS One. 2012;7(10):e46691
references: 23049713